Reglagene is delighted to announce that its shareholders elected David Bearss, PhD, as Director. Dr. Bearss is a drug development expert. He has led teams that discovered 15 cancer medicines for which Initial New Drug applications were filed at the FDA, leading to human clinical trials. Dr. Bearss is a successful bioentrepreneur with several exits. As founder and CEO of Tolero Pharmaceuticals, he led its acquisition by Sumitomo Dainippon in 2017 for $780M. Dr. Bearss's talents and contributions will accelerate Reglagene's timelines to advancing new cancer medicines into human clinical trials.
Dr. Bearss Elected as Director
Updated: Apr 5, 2021